TRX103
Phase 1Cell therapy
TRX103 is one of 48 biologic programs targeting Uveitis. It is currently in Phase 1.
1
Indications
3
Total Trials
3
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
94 competitors in Uveitis
#DrugCompanyPhaseTrials
1Cellcept
RochePhase 3
Pred Forte
NovartisPhase 3
Roferon-a
RochePhase 3
Olumiant
Eli LillyPhase 3
Rayos
RRoxane Laboratories
Phase 3
Cosentyx
NovartisPhase 3
AIN457
NovartisPhase 3
Zinbryta
RochePhase 2
Avastin
BBio-Thera Solutions
Phase 3
Actemra
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Uveitis1 trial
Hematopoietic Stem Cell Transplant (HSCT)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TRX103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- TTr1X, Inc.